Oligometastases in prostate cancer: Restaging stage IV cancers and new radiotherapy options

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Moreno, Antonio José Conde ^a   Albiach, Carlos Ferrer ^a   Soria, Rodrigo Muelas ^a   Vidal, Verónica González ^a   Gómez, Raquel García ^a   Antequera, María Albert ^a  

^a HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

Author keywords

Prostate metastases; SBRT; SRS

Indexed keywords

ANTINEOPLASTIC AGENT;

ABLATION THERAPY; ACCURACY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED RADIOTHERAPY; DIAGNOSTIC TEST; EPIGENETICS; HUMAN; LYMPH NODE METASTASIS; METASTASIS; METASTASIS POTENTIAL; OLIGOMETASTASIS; PROSTATE CANCER; PROSTATE SURGERY; RADIATION DOSE FRACTIONATION; REPEAT PROCEDURE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY;

EID: 84928738553     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-014-0258-7     Document Type: Review

References (97)

1. Halsted WS: I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907, 46:1-19.
2. Fisher B: Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 1980, 40:3863-3874.
3. Fisher B: From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer 1999, 35(14):1963-1973.
4. Karnofsky HS, Lecture M: Natural history of small breast cancers. J Clin Oncol 1994, 12:2229-2234.
5. Hellman S, Weichselbaum RR: Importance of local control in an era of systemic therapy. Nat Clin Pract Oncol 2005, 2:60-61.
6. Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 1995, 13:8-10.
7. Gupta GP, Massague J: Cancer metastasis: building a framework. Cell 2006, 127:679-695.
8. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2(8):584-593.
9. Ribatti D, Mangialardi G, Vacca A: Stephen Paget and the 'seed and soil' theory of metastatic dissemination. Clin Exp Med 2006, 6:145-149.
10. Hahnfeldt P: The host support niche as a control point for tumor dormancy: implications for tumor development and beyond. Adv Exp Med Biol 2013, 734:19-35.
11. Vesely MD, Schreiber RD: Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013, 1284:1-5.
12. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, et al: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
13. Drier Y, Lawrence MS, Carter SL, Stewart C, Gabriel SB, Lander ES, Meyerson M, Beroukhim R, Getz G: Somatic rearrangements across cancer reveal classesof samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res 2013, 23:228-235.
14. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.
15. Niibe Y, Hayakawa K: Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010, 40:107-111.
16. Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, Yamashita H: Oligometastases/Oligo-Recurrence of Lung Cancer. Pulm Med 2013, 2013:438236. doi:10.1155/2013/438236.
17. Rubin P, Brasacchio R, Katz A: Solitary metastases: illusion versus reality. Semin Radiat Oncol 2006, 16:120-130.
18. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31(5):578-583.
19. Saitoh H, Yoshida K, Uchijima Y, Kobayashi N, Suwata J, Kamata S: Two different lymph node metastatic patterns of a prostate cancer. Cancer 1990, 65:1843-1846.
20. Fabozzi SJ, Schellhammer PF, El-Mahdi AM: Pulmonary metastases from prostate cancer. Cancer 1995, 75:2706-2709.
21. Byun WM, Shin SO, Chang Y, Lee SJ, Finsterbusch J, Frahm J: Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol 2002, 23(6):906-912.
22. Padhani AR, Koh D-M, Collins DJ: Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011, 261(3):700-718.
23. Koh D-M, Collins DJ: Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol 2007, 188(6):1622-1635.
24. Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H: Whole-body diffusion-weighted MRI compared with 18F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. Am J Roentgenol 2012, 199(5):1114-1120.
25. Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, Luboldt HJ: Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-Choline PET/CT for detection of bone metastases. Radiology 2008, 249(3):1017-1025.
26. Wu L-M, Gu H-Y, Zheng J, Xu X, Lin L-H, Deng X, Zhang W, Xu JR: Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging 2011, 34(1):128-135.
27. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, Matarrese M, Matei DV, De Cobelli F, Del Maschio A, Rocco F, Rigatti P, Fazio F: Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003, 169:1337-1340.
28. Richter JA, Rodriguez M, Rioja J, Peñuelas I, Martí-Climent J, Garrastachu P, Quincoces G, Zudaire J, García-Velloso MJ: Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 2010, 12:210-217.
29. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI: Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med 2012, 37(7):637-643.
30. Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H: Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 2012, 199(5):1114-1120.
31. Hellman S, Weichselbaum RR: Oligometastases. JCO 1995, 13(1):8-10.
32. Simoncic U, Perlman S, Liu G, Staab MJ, Straus J, Jeraj R: Comparison of NaF and FDG PET/CT for assessment of treatment response in castrate-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 2014. doi:10.1016/j.clgc.2014.07.001. [Epub ahead of print]
33. Sampath SC, Mosci C, Lutz AM, Willmann JK, Mittra E S, Gambhir SS, Iagaru A: Detection of Osseous Metastasis by 18F-NaF/18F-FDG PET/CT Versus CT Alone. Clin Nucl Med 2014. [Epub ahead of print]
34. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM: The role of 11C-Coline and 18F_Fluorochoine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Assoc Urol 2013. [Epub ahead of print]
35. Kjolhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O: Combined (18) F- fluorocholine and (18) F-fluoride positron emission tomography/ computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012, 110:1501-1506.
36. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, Messa C: [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012, 39:13-26.
37. Murphy RC, Kawashima A, Peller PJ: The utility of 11C-choline PET/CT for imaging prostate cancer: a pictorial guide. AJR Am J Roent Genol 2011, 196:1390-1398.
38. Prostate Cancer. NCCN Guidelines. Version 1.14. NCCN.org.
39. Rectal Cancer. NCCN Guidelines. Version 3.14. NCCN.org.
40. Non Small Cell Lung Cancer. NCCN Guidelines. Version 1.14. NCCN.org.
41. Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J: A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine 2005, 30(19):2186-2191.
42. Wang M, Bünger CE, Li H, Wu C, Høy K, Niedermann B, Helmig P, Wang Y, Jensen AB, Schättiger K, Hansen ES: Predictive value of Tokuhashi scoring systems in spinal metastases, focusing on various primary tumor groups. Spine 2012, 37(7):573-582.
43. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P: Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 2004, 58(1):3-10.
44. Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G: Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 2014, 74:297-305.
45. Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, Fiorino C, Kirienko M, Incerti E, Messa C, Gianolli L, Di Muzio N: 11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 2014, 41(7):1270-1279.
46. Tomita K: Surgical strategy for spinal metastases. Spine 2001, 26(3):298-306.
47. Leithner A, Radl R, Gruber G, Hochegger M, Leithner K, Welkerling H, Rehak P, Windhager R: Predictive value of seven preoperative prognostic scoring systems for spinal metastases. Eur Spine J 2008, 17(11):1488-1495. Doi: 10.1007/s00586-008-0763-1. Epub 2008 Sep 12.
48. Popovic M, Lemke M, Zeng L, Chen E, Nguyen J, Thavarajah N, DiGiovanni J, Caporusso F, Chow E: Comparing prognostic factors in patients with spinal metastases: a literature review. Expert Rev Pharmacoecon Outcomes Res 2012, 12(3):345-356.
49. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B: Direct descompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomized trial. Lancet 2005, 366(9486):643-648.
50. Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, Harrop JS, Fehlings MG, Boriani S, Chou D, Schmidt MH, Polly DW, Biagini R, Burch S, Dekutoski MB, Ganju A, Gerszten PC, Gokaslan ZL, Groff MW, Liebsch NJ, Mendel E, Okuno SH, Patel S, Rhines LD, Rose PS, Sciubba DM, Sundaresan N, Tomita K, Varga PP, Vialle LR, et al: A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine 2010, 35(22):E1221-E1229.
51. Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJ, Basic H, Bajrovic A, Hoskin PJ, Tribius S, Wildfang I, Rudat V, Engenhart-Cabilic R, Karstens JH, Alberti W, Dunst J, Schild SE: Prognosis factors for local control and survival after radiotherapy of spinal cord compression. J Clin Oncol 2006, 24(21):3388-3393.
52. Rades D, Huttenlocher S, Dunst J, Bajrovic A, Karstens JH, Rudat V, Schild SE: Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol 2010, 28(22):3597-3604.
53. Rades D, Huttenlocher S, Bajrovic A, Karstens JH, Adamietz IA, Kazic N, Rudat V, Schild SE: Surgery followed by radiotherapy versus radiotherapy alone for metastatic spinal cord compression from unfavorable tumors. Int J Radiat Oncol Biol Phys 2011, 81(5):e861-e868.
54. Laufer I, Rubin DG, Lis E, Cox BW, Stubblefield MD, Yamada Y, Bilsky MH: The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 2013, 18(6):744-751.
55. RTOG 0631 Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0631
56. Gerszten PC, Mendel E, Yamada Y: Radiotherapy and radiosurgery for metastatic spine disease: What are the options, indications, and outcomes. Spine 2009, 34(22S):S78-S92.
57. Chao ST, Koyfman SA, Woody N, Angelov L, Soeder SL, Reddy CA, Rybicki LA, Djemil T, Suh JH: Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases. Int J Radiat Oncol Biol Phys 2012, 82(5):1738-1743.
58. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M: Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 2013, 31(4):455-460.
59. Verhagen PC, Schröder FH, Collette L, Bangma CH: Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 2010, 58(2):261-269. doi:10.1016/j.eururo.2010.05.027. Epub 2010 May 27.
60. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S: Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013, 123(11):4918-4922.
61. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, Drendel V, Schwardt M, Jandausch A, Schultze-Seemann W: Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012, 188(6):2190-2197.
62. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F: Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011, 60(5):935-943.
63. Suardi N, Briganti A, Salonia A, Rigatti P: Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence. Curr Opin Urol 2011, 21(3):237-240.
64. Karnes RJ , Murphy C, Lowe V, Mynderse L, Kwon, Rochester E. Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by 11C-Choline Positron Emission Tomography/Computed Tomography. Abstract: PIV-02 AUA Meeting 2014.
65. Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, Freschi M, Montorsi F, Briganti A: Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol 2014, 32(1):38. e9-16.
66. Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, Castiglioni S, Carnaghi C, Tronconi MC, Santoro A, Scorsetti M: Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys 2011, 81(3):831-838.
67. Almaghrabi MY, Supiot S, Paris F, Mahé MA, Rio E: Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. Radiat Oncol 2012, 7:126.
68. National Radiotherapy Implementation Group Report: Stereotactic body radiotherapy: Clinical Review of the Evidence for SBRT. London: NHS; 2010.
69. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL: Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012, 2:210-225.
70. Withers HR, Lee SP: Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 2006, 16:111-119.
71. Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich JL, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, Weichselbaum RR: Oligo-and polymetastatic progression in lung metástasis patients is associated with specific micro-RNA. Plos One 2012, 7(12):e50141.
72. Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR: Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis 2014, 31(6):735-748.
73. Greco C, Zelefsky MJ, Lovelock M, Fuks Z, Hunt M, Rosenzweig K, Zatcky J, Kim B, Yamada Y: Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys 2011, 79(4):1151-1157.
74. Truman JP, García-Barros M, Kaag M, Hambardzumyan D, Stancevic B, Chan M, Fuks Z, Kolesnick R, Haimovitz-Friedman A: Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One 2010, 30:5(9). doi:10.1371/annotation/6e222ad5-b175-4a00-9d04-4d120568a897.
75. Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, Wilson GD: The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011, 2011:439752.
76. Lara PC, López-Peñalver JJ, Farias VD, Ruiz-Ruiz MC, Oliver FJ, Ruiz de Almodóvar JM. Direct and bystander radiation effects: A biophysical model and clinical perspectives. Cancer Lett 2013. doi:10.1016/j.canlet.2013.09.006. [Epub ahead of print]
77. Westdorp H, Sköld AE, Snijer BA, Franik S, Mulder SF, Major PP, Foley R, Gerritsen WR, de Vries IJM: Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol. 2014, 5:191.
78. Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y: International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2012, 83(5):e597-e605.
79. Matuszak MM, Yan D, Grills I, Martinez A: Clinical applications of volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2010, 77(2):608-616.
80. Ferrer AC, Rodríguez CM, Conde Moreno AJ. Radioterapia Guiada por la Imagen. Cáncer de Próstata: Enfoque Multidisciplinar. Grupo URONC-OR SEOR. Editado por Medical Practice Group.2007: 365-384
81. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR: Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2012, 118(11):2962-2970.
82. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, Ratib O, Weber DC, Miralbell R: Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 2013, 52(8):1622-1628.
83. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M: (18) fluooethylcoline-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-pocitive lymph nodes. Radiat Oncol 2011, 6:44.
84. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, Gulisano M, Aterini S: Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011, 9(1):49-55.
85. Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, Cambria R, Brait L, Possanzini M, Bianchi LC, Vavassori A, Zerini D, Orsi F, de Cobelli O, Orecchia R: Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 2009, 93(1):14-17.
86. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R: Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(2):889-897.
87. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P. Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy. Clin Genitourin Cancer 2012. [Epub ahead of print]
88. Non-systemic Treatment for Patients with Low-volume Metastatic Prostate Cancer https://clinicaltrials.gov/ct2/show/NCT01558427
89. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR: Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2013, 2:215.
90. Brown JM, Carlson DJ, Brenner DJ: The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 2014, 88(2):254-262.
91. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology: EUA guidelines on prostate cáncer. Part II: Treatment of advanced, relapsing and castration-resistant prostate cancer. Eur Urol 2014, 65(2):467-479.
92. Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT02192788
93. Radiotherapy for Oligometastatic Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT01859221?term=NCT01859221&rank=1
94. Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT02206334
95. Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ: Stereotatic body radiotherapy for oligometastases. Lancet 2013, 14(1):e28-e37. Doi:10.1016 (S1470-2045 (12) 70510-7. Review. PMID: 23276369.
96. Zeng J, Baik C, Bhatia S, Mayr N, Rengan R: Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncol 2014, 15:e426-e434.
97. Alcorn S, Walker AJ, Gandhi N, Narang A, Wild AT, Hales RK, Herman JM, Song DY, Deweese TL, Antonarakis ES, Tran PT: Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer. Int J Mol Sci 2013, 14:14800-14832.